In conclusion, our head-to-head comparator is the first preclinical study that has shown that the sGC activator Bay 60 is superior to Bay 41 and that Bay 60 has potential therapeutic promise in the treatment of diabetes-associated vascular complications. This evidence concerns the gene SGCB and diabetes mellitus.